Ann-Jean C. C. Beck

Ann-Jean C. C. Beck

Auto-generated profile, based on publicly available information

Ann-Jean C. C. Beck

Department of Head and Neck Oncology and Surgery Netherlands Cancer Institute Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 December 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAnn-Jean C C Beck
Ann-Jean C C Beck
JKJacobien M Kieffer
Jacobien M Kieffer
VRValesca P. Retel
Valesca P. Retel
LOLydia F J Van Overveld
Lydia F J Van Overveld
RTRobert P Takes
Robert P Takes
MSMartijn M Stuiver
Martijn M Stuiver
Innovations in head and neck cancer (HNC) treatment are often subject to economic evaluation prior to their reimbursement and subsequent access for patients. Mapping functions facilitate economic evaluation of new treatments when the required utility data is absent, but quality of life data is available. The objective of this study is to develop a mapping function translating the EORTC QLQ-C30 to EQ-5D-derived utilities for HNC through regression modeling, and to explore the added value of disease-specific EORTC QLQ-H&N35 scales to the model. Data was obtained on patients with primary HNC treated with curative intent derived from two hospitals. Model development was conducted in two phases: 1. Predictor selection based on theory- and data-driven methods, resulting in three sets of potential predictors from the quality of life questionnaires; 2. Selection of the best out of four methods: ordinary-least squares, mixed-effects linear, Cox and beta regression, using the first set of predictors from EORTC QLQ-C30 scales with most correspondence to EQ-5D dimensions. Using a stepwise approach, we assessed added values of predictors in the other two sets. Model fit was assessed using Akaike and Bayesian Information Criterion (AIC and BIC) and model performance was evaluated by MAE, RMSE and limits of agreement (LOA). The beta regression model showed best model fit, with global health status, physical-, role- and emotional functioning and pain scales as predictors. Adding HNC-specific scales did not improve the model. Model performance was reasonable; R2 = 0.39, MAE = 0.0949, RMSE = 0.1209, 95% LOA of -0.243 to 0.231 (bias -0.01), with an error correlation of 0.32. The estimated shrinkage factor was 0.90. Selected scales from the EORTC QLQ-C30 can be used to estimate utilities for HNC using beta regression. Including EORTC QLQ-H&N35 scales does not improve the mapping function. The mapping model may serve as a tool to enable cost-effectiveness analyses of innovative HNC treatments, for example for reimbursement issues. Further research should assess the robustness and generalizability of the function by validating the model in an external cohort of HNC patients.

1 December 2019 in Health Policy
Verified
Journal Article
Closed access
ABAcc Beck
Acc Beck
VRVp Retèl
Vp Retèl
PBPa Bhairosing
Pa Bhairosing
Michiel Van den BrekelMichiel Van den Brekel
Michiel Van den Brekel
WHWim van Harten
Wim van Harten

21 May 2018 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
ABAnn-Jean C. C. Beck
Ann-Jean C. C. Beck
PLPeter J. F. M. Lohuis
Peter J. F. M. Lohuis
AAAbrahim Al-Mamgani
Abrahim Al-Mamgani
LSLaura A. Smit
Laura A. Smit
WKWillem M. C. Klop
Willem M. C. Klop

4 September 2020 in Head & Neck
Verified
Journal Article
Closed access
PDF file
ABAnn‐Jean C. C. Beck
Ann‐Jean C. C. Beck
VRValesca P. Retel
Valesca P. Retel
GBGlenn Bunting
Glenn Bunting
RSRosh K. V. Sethi
Rosh K. V. Sethi
DDDaniel G. Deschler
Daniel G. Deschler
WHWim H. van Harten
Wim H. van Harten

10 August 2020 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
ABAnn‐Jean C. C. Beck
Ann‐Jean C. C. Beck
WHWim H. van Harten
Wim H. van Harten
Michiel Van den BrekelMichiel Van den Brekel
Michiel Van den Brekel
ANArash Navran
Arash Navran
VRValesca P. Retel
Valesca P. Retel

1 April 2019 in Oral Oncology
Verified
Journal Article
Open access
ABA.C.C. Beck
A.C.C. Beck
VRValesca P. Retel
Valesca P. Retel
Michiel Van den BrekelMichiel Van den Brekel
Michiel Van den Brekel
WHWim van Harten
Wim van Harten
Patient access to the voice prosthesis and heat and moisture exchanger (HME) is not always guaranteed in Europe. Therefore, the aim of this qualitative study is to evaluate factors influencing physician's prescription and reimbursement of these devices in eight European countries, and to identify barriers of and facilitators to effective patient access. In this mixed methods study, we conducted a survey among stakeholders evaluating prescription (Part 1 of the survey), reimbursement (Part 2), and barriers of and facilitators to effective patient access (Part 3). Part 1 was completed by head and neck surgeons employed in France, Germany, the United Kingdom, Italy, Spain, Belgium, the Netherlands and Poland. Part 2 and 3 were completed by medical device company representatives in respective countries, followed by semi-structured interviews. Based on the survey, filled in by 36 surgeons, all prescribed the voice prosthesis. Four surgeons didn't prescribe the HME in Italy and Poland due to lack of both reimbursement and experience/training, and feeling uncomfortable with device use. Most restrictive factors (e.g. increased workload, insufficient staff) occurred in countries with decentralized healthcare systems including Spain and Italy. Non-HME-usage was influenced by economical and physician-related factors. Restrictive factors were related to limited regional device reimbursement and provision. Nationwide reimbursement, guideline implementation, support for physicians by training/education and providing a rehabilitation team will increase device use.